{Reference Type}: Journal Article
{Title}: The TREK-1 potassium channel is involved in both the analgesic and anti-proliferative effects of riluzole in bone cancer pain.
{Author}: Delanne-Cuménal M;Lamoine S;Meleine M;Aissouni Y;Prival L;Fereyrolles M;Barbier J;Cercy C;Boudieu L;Schopp J;Lazdunski M;Eschalier A;Lolignier S;Busserolles J;
{Journal}: Biomed Pharmacother
{Volume}: 176
{Issue}: 0
{Year}: 2024 Jul 7
{Factor}: 7.419
{DOI}: 10.1016/j.biopha.2024.116887
{Abstract}: <B>BACKGROUND: </B>The metastasis of tumors into bone tissue typically leads to intractable pain that is both very disabling and particularly difficult to manage. We investigated here whether riluzole could have beneficial effects for the treatment of prostate cancer-induced bone pain and how it could influence the development of bone metastasis.<BR><B>METHODS: </B>We used a bone pain model induced by intratibial injection of human PC3 prostate cancer cells into male SCID mice treated or not with riluzole administered in drinking water. We also used riluzole in vitro to assess its possible effect on PC3 cell viability and functionality, using patch-clamp.<BR><B>RESULTS: </B>Riluzole had a significant preventive effect on both evoked and spontaneous pain involving the TREK-1 potassium channel. Riluzole did not interfere with PC3-induced bone loss or bone remodeling in vivo. It also significantly decreased PC3 cell viability in vitro. The antiproliferative effect of riluzole is correlated with a TREK-1-dependent membrane hyperpolarization in these cells.<BR><B>CONCLUSIONS: </B>The present data suggest that riluzole could be very useful to manage evoked and spontaneous hypersensitivity in cancer-induced bone pain and has no significant adverse effect on cancer progression.